Versant Ventures

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.

Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ.

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

The Foundry, LLC is the premier medical device company incubator. We work with inventors to rapidly transform their concepts into companies by providing an incomparable combination of leadership, an experienced, multi-disciplinary team, a state-of-the-art facility and an extensive funding network. The Foundry Team is comprised of veteran medical device entrepreneurs and investors with real world experience—and success—in developing world class medical device companies.

Microfabrica Inc. designs and develops micro-scale additive manufacturing solutions. The company offers a process that combines 3D printing that enables structures to be built layer by layer. Its process creates objects from layers of metal to produce extremely refined structures. The company also provides minuscule surgical instruments, including biopsy forceps and a tissue scaffold with linkages that allow it to expand with cell growth. It serves to aerospace, electronics, medical devices, and other industries. Microfabrica Inc. was formerly known as MEMGen Corporation and changed its name to Microfabrica Inc. in September 2003. The company was founded in 1999 and is headquartered in Van Nuys, California with an additional office in Santa Clara, California. As of May 20, 2019, Microfabrica Inc. operates as a subsidiary of Technoprobe S.p.A.

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Cotera, Inc. designs and develops implants that shift muscles and tendons to redirect the forces they exert on joints. Its portfolio includes Latella device, an implant that is attached to the thigh bone (femur) through a surgical procedure for treating patients with medial knee pain due to osteoarthritis. The company was founded in 2011 and is based in Menlo Park, California.

Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

Presbyopia Therapies LLC moves forward with development of its Liquid Vision drops, a temporary presbyopia-correcting therapeutic designed to last five hours or longer.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

SeqLL True Single Molecule Sequencing | DNA & RNA Sequencing Services

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

SeqLL True Single Molecule Sequencing | DNA & RNA Sequencing Services

Matterhorn is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on the surface of cancer cells that are recognized and killed by T cells bearing a MR1-specific T cell receptor.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Ebb Therapeutics, Inc. develops regional cerebral thermal therapy (RCTT) device for use in insomnia and sleep disorders. It offers Ebb Insomnia Therapy, a drug-free insomnia therapy. Ebb Therapeutics, Inc. was formerly known as Cereve, Inc. Ebb Therapeutics, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

Kinestral Technologies, Inc. manufactures smart-tinting glass for commercial and residential purposes. The company's products include Halio, smart-tinting glass supported by Halio software application that can integrate with smart homes and automation systems; Halio Tint Selector, a wireless device that enables local control of a pre-selected window or group of windows; Halio Cloud, an application program interface to integrate window operations with building automation systems. The company has strategic alliance with Asahi Glass Co., Ltd. The company was incorporated in 2010 and is based in Hayward, California with a location in Salt Lake City, Utah.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Laguna Pharmaceuticals Inc. develops and markets drugs and small molecule pharmaceuticals vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company was formerly known as ChanRx Corp. and changed its name to Laguna Pharmaceuticals Inc. in February, 2015. Laguna Pharmaceuticals Inc. was founded in 2006 and is based in La Jolla, California.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

SeqLL True Single Molecule Sequencing | DNA & RNA Sequencing Services

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Century Therapeutics, Inc. engages in the development of induced pluripotent stem cell- (iPSC) based drugs for the treatment of hematologic and solid malignancies. The use of iPSC enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply allogeneic, homogeneous therapeutic products. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Biospect, Inc. is developing minimally invasive technology for identifying and assaying protein biomarker patterns that reflect and differentiate biological states. The integrated Biospect system consists of proprietary separations, detection and informatics technologies, and is targeted for use in diagnosing and managing disease or drug development. Biospect is backed by Advent Venture Partners, Prospect Venture Partners, Venrock Associates and Versant Ventures and was incubated by Prospect Venture Partners.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Aria Biosystems is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Aria utilizes proprietary bio-layer interferometry (BLI) that enables self-calibration and measurement of molecular interactions using simple-to-use and inexpensive instrumentation. The entire analysis can be completed within minutes and does not require labeling of either probe or target. Aria's analytical capabilities provide greater value in applications where existing methods such as HPLC, ELISA and surface plasmon resonance (SPR) have limitations in throughput, performance and cost.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Kyras Therapeutics is a biotech company. According to data from the National Cancer Institute, more than 30 percent of all human cancers are driven by mutations in RAS genes, including 95% of pancreatic, 45% of colorectal, and 35% of lung cancers, among many others.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

OraMetrix, Inc. provides 3-D technology solutions for facilitating and improving the quality of orthodontic care. It offers an orthodontic treatment system that allows the use of precision digital tools throughout the diagnosis, treatment planning and monitoring, and arch wire customization processes of the orthodontic treatment. OraMetrix, Inc. was formerly known as Orthotel, Inc. The company was founded in 1998 and is based in Richardson, Texas with an additional office in Berlin, Germany.

Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing. CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Syrrx Inc focuses on drug targets that have been validated in human clinical trials and directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation. Syrrx exploits its competitive advantage in high-throughput structural biology to be the first organization to determine the three dimensional structure of known drug targets. Syrrx then uses these structures to drive iterative, structure-based drug design programs to efficiently generate potential drug candidates. Syrrx has an ongoing partnership for the development and commercialization of Syrrx-designed human dipeptidyl peptidase IV (DPP IV) inhibitors as drug products for the treatment of type 2 diabetes and other major human diseases. Syrrx also has a strategic alliance for the discovery and early development of inhibitors targeting human HDACs and HSD1.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central pain processing mechanisms.

Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

Metavention, Inc. was incorporated in 2012 and is based in Dover, Delaware.

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.

Inception IBD is focused on translating academic discoveries in the field of IBD

OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.

Inceptus is a medical device company incubator with a mission to create and foster innovative concepts into companies by providing a combination of experienced engineering, clinical research expertise, seasoned leadership and strong financial resources. The Inceptus team includes talented medical device engineers, serial entrepreneurs, executive managers and investors with a successful track record in the formation of medical device companies.

Nanoplex Technologies is developing nanoparticle-based products for life science research, for ultra-sensitive molecular identification and quantitation, and for authentication and tracking applications. The company's goal is to rapidly convert state-of-the-art nanoscience into practical and valuable products.

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Veran Medical Technologies is an image-guided medical device company that helps physicians diagnose disease and deliver therapies. It develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast-enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. The company was incorporated in 2007 and is headquartered in St. Louis, Missouri.

RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

As of April 12, 2019, Vital Therapies, Inc. was acquired by Immunic AG, in a reverse merger transaction. Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is based in San Diego, California.

Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.

Acclarent, Inc. is a medical device company in Menlo Park, CA that was established in June of 2004. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplastyâ„¢ devices. Through the Balloon Sinuplastyâ„¢ technology and our RelievaÂ:registered: product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT.

Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Acclarent, Inc. is a medical device company in Menlo Park, CA that was established in June of 2004. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplastyâ„¢ devices. Through the Balloon Sinuplastyâ„¢ technology and our RelievaÂ:registered: product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT.

The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.

Intersection Medical, Inc. develops and markets non-invasive medical devices. Its devices help physicians in treating patients with heart failure. The company was founded in 2006 and is based in Carlsbad, California.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

"The New Standard of Care in Rehab and Conditioning" With leading-edge differential air pressure technology (DAP), AlterG® is changing the 'weight' of the world. Our rehabilitation equipment enables individuals to improve mobility and health, recover from injury and surgery more effectively, overcome medical challenges that limit movement, and enhance athletic conditioning.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

PhaseRx is a startup company based in Seattle focused on the delivery of siRNA and other macromolecular therapeutics. The Company has attracted top-tier venture investors and was founded by its President, Robert Overell, Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company's Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company believes the technology also has significant applications for the delivery of other macromolecular therapeutics.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

A healthcare information technology company, provides telecardiology and image archiving solutions for hospitals, cardiovascular core labs, and clinical trial sponsors. It offers storing and sharing of patient images and data for cardiology community. The company was founded in 1999 and is based in Daly City, California.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.

RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Impedance Cardiology Systems, Inc. engages in biotechnology and is based in Menlo Park, California.

Acclarent, Inc. is a medical device company in Menlo Park, CA that was established in June of 2004. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplastyâ„¢ devices. Through the Balloon Sinuplastyâ„¢ technology and our RelievaÂ:registered: product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significant experience developing medical devices for the spine industry. Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA.

Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome. The company's products in the clinical pipeline include JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-8, a formulation incorporating a benzodiazepine, for the treatment of acute repetitive seizure clusters in refractory epilepsy patients. Its pipeline also comprise JZP-7, a formulation incorporating a dopamine agonist for the treatment of restless legs syndrome; and JZP-2, a formulation of a benzodiazepine for the acute treatment of panic attacks associated with panic disorder. The company has a product development and license agreement with Antares Pharma, Inc. Jazz Pharmaceuticals was founded in 2003 and is headquartered in Palo Alto, California.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significant experience developing medical devices for the spine industry. Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA.

Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap and Advanced Tech­nol­ogy Ventures.

Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

AAVLife provides gene therapy services. It conducts clinical trials. The company was founded in 2014 and is based in Paris, France.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Founded in 2011, Inception Sciences is a small molecule pharmaceutical incubator. Their focus is on creating high-value therapies with transformative potential to address diseases and disorders with significant unmet needs. Through partnerships with academic experts, they are translating biological insights into highly-targeted, novel drugs. Their team has a proven track record of drug discovery, having played pivotal roles in the discovery of clinical-stage compounds for the treatment of fibrosis, asthma, and COPD at Amira Pharmaceuticals, and of several high-profile drugs at Merck.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. The Ceterix technology enables surgeons to place stitches in very tight joint compartments, while protecting sensitive surrounding structures such as nerves, arteries and cartilage. This technology has applications in numerous arthroscopic procedures in knees, hips and shoulders. Ceterix was established in October 2010. The company was founded based on the inventions of Dr. Justin Saliman, an orthopaedic surgeon specializing in sports medicine. Dr. Saliman envisioned improving the outcomes of arthroscopic procedures by enabling surgeons to place suture patterns that today can be done only in open procedures, if at all. Ceterix is based in Menlo Park, California.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Currently serving the San Francisco Bay Area as a licensed General Contractor, Skylight delivers full service renovations for kitchens, bathrooms and other interior spaces. The Skylight process is fully digital and fully integrated – from planning the space based on lifestyle, to personalized curation of materials, right through to permitting, construction and the final close-out package. Skylight was created to fix the problems with the traditional renovation experience.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.

Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.

Currently serving the San Francisco Bay Area as a licensed General Contractor, Skylight delivers full service renovations for kitchens, bathrooms and other interior spaces. The Skylight process is fully digital and fully integrated – from planning the space based on lifestyle, to personalized curation of materials, right through to permitting, construction and the final close-out package. Skylight was created to fix the problems with the traditional renovation experience.

Kinestral Technologies, Inc. manufactures smart-tinting glass for commercial and residential purposes. The company's products include Halio, smart-tinting glass supported by Halio software application that can integrate with smart homes and automation systems; Halio Tint Selector, a wireless device that enables local control of a pre-selected window or group of windows; Halio Cloud, an application program interface to integrate window operations with building automation systems. The company has strategic alliance with Asahi Glass Co., Ltd. The company was incorporated in 2010 and is based in Hayward, California with a location in Salt Lake City, Utah.

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap and Advanced Tech­nol­ogy Ventures.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

BlueRock Therapeutics LP develops, manufactures, and delivers engineered cell therapies in the fields of neurology, cardiology, and immunology by using CELL+GENE platform. It also offers stable master cell banks, such as, healthy donor cells; induced pluripotent stem cells; allo-engineering for immune evasion; and culturing and expansion. The company was founded in 2016 and is based in Cambridge, Massachusetts with additional offices in New York, New York; and Toronto, Canada. As of September 30, 2019, BlueRock Therapeutics LP operates as a subsidiary of Bayer Aktiengesellschaft.

Concuity is a leading provider of revenue cycle management software and services specializing in contract profitability, contract compliance, denial management, and revenue process and lifecycle improvement. Concuity delivers a 100% web-based, highly scalable solution that provides healthcare organizations the visibility and control they need to create and negotiate fair contracts, comply with contractual obligations, and identify and recover on underpaid and denied accounts. Concuity's solutions incorporate your unique business rules and payer terms — so that you can obtain greater visibility and more efficiently manage your revenue throughout its lifecycle.

HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

Gotham Therapeutics Corp. operates as a biotechnology company, which develops a novel drug class targeting epitranscriptomics machinery. It develops new treatments for patients suffering from cancers, autoimmune, and neurodegenerative diseases by changing the activity of proteins that modify messenger ribonucleic acid (mRNA). The company was founded in 2017 and is based in New York, New York.

"The New Standard of Care in Rehab and Conditioning" With leading-edge differential air pressure technology (DAP), AlterG® is changing the 'weight' of the world. Our rehabilitation equipment enables individuals to improve mobility and health, recover from injury and surgery more effectively, overcome medical challenges that limit movement, and enhance athletic conditioning.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Concuity is a leading provider of revenue cycle management software and services specializing in contract profitability, contract compliance, denial management, and revenue process and lifecycle improvement. Concuity delivers a 100% web-based, highly scalable solution that provides healthcare organizations the visibility and control they need to create and negotiate fair contracts, comply with contractual obligations, and identify and recover on underpaid and denied accounts. Concuity's solutions incorporate your unique business rules and payer terms — so that you can obtain greater visibility and more efficiently manage your revenue throughout its lifecycle.

Minerva Surgical Inc., a medical technology company, develops products for women’s healthcare. It offers The Minerva Endometrial Ablation System, a product for the treatment of abnormal uterine bleeding in women. Minerva Surgical Inc. was founded in 2008 and is based in Redwood City, California.

Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

Monteris Medical is a medical device venture that develops new technologies for the treatment of cancer. It is a private equity-backed neurosurgical company focused solely on diseases of the brain. It develops MRI-guided, laser-based systems designed for the ablation of brain lesions. The company's system applies focused laser energy to ablate brain tumors from the inside, with little or no effect on surrounding healthy tissue as well as provides clinicians a new neurosurgical tool that offers real-time control and visualization of the therapy during laser ablation treatment, enabling neurosurgeons to ablate (treat with lethal heat) brain lesions and brain tumors that may be difficult to approach via traditional methods. It was founded in 1999 and has offices in Minneapolis, Minnesota, USA and Winnipeg, Manitoba, Canada.

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Veran Medical Technologies is an image-guided medical device company that helps physicians diagnose disease and deliver therapies. It develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast-enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. The company was incorporated in 2007 and is headquartered in St. Louis, Missouri.

Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

Rennovia, Inc. produces renewable chemicals. It offers adipic acids and adiponitrile for consumer-end products, including carpets, heat-resistant automotive parts, furniture, apparel, footwear, luggage, adhesives, and coatings. Rennovia was incorporated in 2009 and is based in Menlo Park, California.

Jecure Therapeutics, Inc., a biotechnology company, develops and creates small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Its small-molecule therapeutics is used to block inflammasome activation and disrupt the sterile inflammation loop that results in hepatocellular injury and cell death. Jecure Therapeutics, Inc. was incorporated in 2015 and is based in San Diego, California. As of 2018, Jecure Therapeutics, Inc. operates as a subsidiary of Genentech, Inc.

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

LensX Lasers is a maker of surgical lasers used to repair cataracts.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

Hotspur Technologies is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company's products are based on unique and groundbreaking technology that opens blood vessels more efficiently and less invasively.

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing. CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing. CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Century Therapeutics, Inc. engages in the development of induced pluripotent stem cell- (iPSC) based drugs for the treatment of hematologic and solid malignancies. The use of iPSC enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply allogeneic, homogeneous therapeutic products. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

NewHope Bariatrics, Inc. develops and operates ambulatory surgery centers and short-stay surgical hospitals that serve the needs of the morbidly obese. It offers bariatric care services to men, women, and children suffering from obesity.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.